



## Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

May 18, 2023

**Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073**

SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference taking place May 19-24, 2023, in Washington, DC.

"These data demonstrate the power of our GPCR structure-based drug discovery technology across broad therapeutic areas including cardiopulmonary diseases," said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. "In close partnership with Schrödinger's computational capabilities, we designed and discovered potential best-in-class orally available novel small molecules against the LPAR1 and APJR receptors which we are excited to continue to advance."

Clinical and pre-clinical presentations include:

**Poster presentation (P1059):** [Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 \(LPAR1\)](#)

- **Date:** Sunday, May 21, 2023
- **Presentation Time:** 11:30 a.m. – 1:15 p.m. ET
- **Session (A67):** Biomarkers, Mediators, and Translational Models for ILD

**Poster presentation (P207):** [A First-in-Human Single/Multiple Ascending Dose Study of ANPA-0073, a Novel Small Molecule G-protein Biased Apelin Receptor Agonist, in Healthy Volunteers](#)

- **Date:** Monday, May 22, 2023
- **Presentation Time:** 11:30 p.m. – 1:15 p.m. ET
- **Session (B59):** Breaking Bad: New Drugs and Formulations for Pulmonary Hypertension

**Poster presentation (P925):** [Discovery of G-protein Biased APJ Agonist Small Molecule for Pulmonary Diseases](#)

- **Date:** Wednesday, May 24, 2023
- **Presentation Time:** 12:00 p.m. – 2:00 p.m. ET
- **Session (D108):** Cells, Signaling, and Mediators in Lung Remodeling and Fibrosis

A copy of the presentation materials can be accessed by visiting the "Presentations" section of the Structure Therapeutics website after the conclusion of the presentations and will be archived on the Structure Therapeutics website.

### About Structure Therapeutics

Structure Therapeutics is a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative oral treatments for chronic metabolic and pulmonary conditions with significant unmet medical need. Utilizing its next generation structure-based drug discovery platform, the company has established a scientifically-driven, GPCR-targeted pipeline, featuring two wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit [www.structuretx.com](http://www.structuretx.com).

### Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the Company's future plans and prospects, the Company's anticipated cash runway, any expectations regarding the safety or efficacy of GSB-1290 and other candidates under development, the ability of GSB-1290 to treat type 2 diabetes, obesity or related indications, plans with respect to regulatory submissions, the planned timing of the Company's clinical trials, data results and continued development of GSB-1290 and expectations regarding an oral development candidate targeting GLP-1R. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the Company's ability to advance GSB-1290, LTSE-2578, ANPA-0073 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company's therapeutic candidates, the timing and results of preclinical and clinical trials, the Company's ability to fund development activities and achieve development goals, the impact of the ongoing COVID-19 pandemic, inflation, supply chain issues, rising interest rates and future bank failures on the Company's business, its ability

to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023 and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

**Contacts:**

**Investors:**

Jun Yoon, Chief Financial Officer  
Structure Therapeutics Inc.  
ir@structuretx.com

**Media:**

Dan Budwick  
1AB  
Dan@1abmedia.com